mRNA licensing agreements rise 800% in value as confidence grows beyond vaccines
Express Pharma
OCTOBER 16, 2024
Messenger ribonucleic acid (mRNA)-based innovator pharmaceuticals saw a staggering 800 per cent increase in licensing agreement deal values from 2019 to 2024YTD, driven by the remarkable success of mRNA vaccines during the COVID-19 pandemic. billion in 2030. Bristol Myers Squibb formed a multi-year, $1.87
Let's personalize your content